QualityStocks would like to highlight Medgenics (NYSE: MDGN), a clinical-stage biopharmaceutical company. Medgenics is developing an innovative and proprietary platform technology - a biological "Biopump" - which allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C.
In the company’s news yesterday,
Medgenics announced that it will be presenting a poster at the upcoming American Society of Nephrology’s Kidney Week 2012, taking place in San Francisco from October 30 to November 4. The poster is titled “Novel Sustained delivery of Erythropoietin in Hemodialysis Patients for Safer Anemia Control Using EPODURE Biopumps – Autologous Dermal Tissue Samples Secreting Erythropoitein.”
The poster will present preliminary data from a Phase IIa clinical trial of EPODURE to treat anemia patients with end stage renal disease. EPODURE is an autologous dermal Biopump, implanted subcutaneously, capable of the sustained secretion of therapeutic erythropoitein (EPO) in the body using a small tissue explant from the patient’s own skin and processed to continuously produce EPO for many months.
Medgenics poster will actually be presented on Friday, November 2. It aims to bring this Biopump and others to market via strategic partnerships with major pharmaceutical and medical device companies.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.